The NUDT15 Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Raji human B lymphoblast cell line. This product constitutes a loss-of-function model of NUDT15, generated by CRISPR/Cas9-mediated gene disruption, yielding a heterogeneous pool of cells with various knockout alleles. The polyclonal format facilitates cost-effective large-scale functional studies and drug screening where clonal selection is not required.
The Raji cell line is a suspension-adapted, Epstein-Barr virus (EBV)-immortalized B lymphocyte originally derived from a male patient with Burkitt’s lymphoma. These lymphoblastoid B cells serve as a standard model for investigating B cell malignancies, signal transduction, and apoptosis. The EBV-positive background is advantageous for probing interactions between viral latency and DNA damage responses in lymphoid cells.
NUDT15 encodes a nucleoside diphosphate hydrolase that sanitizes oxidized nucleotide triphosphates such as 8-oxo-dGTP and 8-oxo-dATP, preventing their DNA incorporation. Functioning downstream of TP53 under oxidative stress, it interacts with PCNA and NUDT1 (MTH1) at replication forks. Loss of NUDT15 disrupts purine metabolism and DNA repair, sensitizing cells to thiopurine antimetabolites due to increased incorporation of thioguanine nucleotides into DNA, a process that can be monitored via OGG1-dependent repair pathways.
Within the Raji B-cell background, the NUDT15 knockout model enables detailed investigation of nucleotide pool sanitation, genomic stability, and drug response in a lymphoma-relevant setting. It is especially suited for studying thiopurine-induced myelosuppression and gene?Cdrug interactions that affect treatment outcomes in acute lymphoblastic leukemia and other B-cell malignancies. The EBV-immortalized nature also permits exploration of how viral oncogenesis intersects with nucleotide metabolism and DNA repair.
This polyclonal knockout product is ideal for pharmacogenomic studies of thiopurine toxicity, DNA damage and repair assays, drug sensitivity screening, and target validation in B-cell models. Typical applications include Western blotting and RT-qPCR for confirming NUDT15 loss, comet assay and ??-H2AX immunofluorescence for DNA damage, MTT and Annexin V flow cytometry for viability/apoptosis, and RNA-seq for transcriptomic profiling. For further details, batch-specific validation, and ordering, please contact Ascent Research.
